Table 3. Cause-specific outcomes by linkage to care in HIV-positive participants.

	Enhanced linkage to care group	Standard linkage to care group	Adjusted* hazard ratio (95% CI)	p value
Early death (≤90 days)	46/483 (10%)	36/482 (7%)	0·87 (0·56–1·35)	0·53
Men	22/176 (13%)	20/184 (11%)	1·04 (0·56–1·93)	0·90
Women	24/307 (8%)	16/298 (5%)	075 (0·39–1·42)	0·37
Death (1 year)	74/483 (15%)	66/482 (14%)	0·97 (0·70–1·36)	0·88
Men	34/176 (19%)	37/184 (20%)	1·23 (0·77–1·97)	0·39
Women	40/307 (13%)	29/298 (10%)	0·80 (0·49–1·29)	0·36
Attended an HIV clinic at most recent medical visit	355/439 (81%)	357/446 (80%)	0·90 (0·77–1·04)	0·17
Men	117/155 (75%)	126/163 (77%)	1·10 (0·85–1·42)	0·48
Women	238/284 (84%)	231/283 (82%)	0·80 (0·66–0·96)	0·02
Received co-trimoxazole	416/439 (95%)	416/446 (93%)	0·95 (0·83–1·09)	0·48
Men	142/155 (92%)	152/163 (93%)	1·07 (0·85–1·35)	0·58
Women	274/284 (96%)	264/283 (93%)	0·89 (0·75–1·06)	0·19
Received antiretroviral therapy (baseline CD4 ≤250 cells per μL)	157/202 (78%)	130/183 (71%)	0·77 (0·60–0·97)	0·03
Men	66/81 (81%)	47/76 (62%)	0·60 (0·41–0·87)	0·008
Women	91/121 (75%)	83/107 (76%)	0·95 (0·70–1·30)	0·76

Interaction between participant sex and linkage to care group, with adjusted models, p≥0·10 for all except: attended HIV clinic (p=0·08) and received antiretroviral therapy (p=0·04).

^*Adjusted for continuous baseline CD4 cell count, and stratified by baseline employment category.